Search Orphan Drug Designations and Approvals
-
Generic Name: | drug component, inhaled nitric oxide, of the inhaled nitric oxice/INOpulse® Device combination product |
---|---|
Date Designated: | 09/10/2019 |
Orphan Designation: | Treatment of idiopathic pulmonary fibrosis |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Bellerophon Therapeutics 184 Liberty Corner Road Suite 302 Warren, New Jersey 07059 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
-